

表格检索 - 如何设置跟踪服务

- 如何设置检索的跟踪服务

以一个药物报告为例

欲从以下标准检索药物：

作用机制 (Action) - EGFR 家族酪氨酸激酶受体抑制剂 (EGFR family tyrosine kinase receptor inhibitor)

治疗领域 (Therapy area) - 肺部肿瘤 (lung tumor)

国家 (Country) - 在美国和日本的进展 (US OR Japan)

The screenshot shows the 'Form Search - Drugs + EphMRA codes' interface. The search criteria are as follows:

- Topic:** (Title, keywords, abstract) Title only
- Company:** [Empty field]
- Drug:** [Empty field]
- Action:** "EGFR family tyrosine kinase receptor inhibitor"
- Therapy area (TA):** "Lung tumor"
- Technology:** [Empty field]
- EphMRA Code:** [Empty field]
- Country:** "US OR Japan"
- Other fields:** Three dropdown menus, each set to "Overview".
- Date:** Added Date (dropdown), with radio buttons for: Current week, Latest 2 weeks, Latest 4 weeks, Year to date, Latest 5 years, and All years.
- Development Status:** Radio buttons for: Highest (Not linked), Linked to TA/Company/Country, Highest linked to TA/Company/Country, Any (Not linked), and Any Status. Under 'Any Status', several checkboxes are selected: Discovery Research, All Clinical, Phase 1, Phase 2, Phase 3, Pre-Registered, Registered, Launched, Discontinued, Suspended, Withdrawn, No Development Reported, and Research Tool.
- Intellectual property:** Include core patents

At the bottom, the 'Structure' section is visible with options for 'Substructure', 'Current molecule type' (Exact), and 'Similarity' (80% Min). The 'Date limit' section has a link to 'Add specific date limit'. At the bottom right, the 'Save' button is highlighted with a yellow box and an arrow pointing to it from the '步骤 2' callout.

步骤 1

在 Form Search Drugs 输入您的检索标准

例

Action:
"EGFR family tyrosine kinase receptor inhibitor"

Therapy area: "Lung tumor"

Country: US OR Japan

步骤 2

检索标准设定完毕后，
点击保存按钮

弹出一个窗口“SAVE FORM SEARCH DRUGS”，提示您已保存“表格检索 - 药物”

SAVE FORM SEARCH - DRUGS

Enter a name for your search: (20 characters max.)

Choose a folder:

步骤 3
输入您的检索名称并选择一个文件夹进行保存

例
 name of the search: lung tumor
 folder: Project1/Searches

完成后点击保存

SAVE FORM SEARCH - DRUGS

Do you want to set an email alert for this Saved Search? Yes No

Enter your email address:

Include colleagues:

步骤 4 设置电子邮件跟踪

Yes : 您可以设置跟踪
 No : 只是保存检索

...然后点击 Next

SAVE FORM SEARCH - DRUGS

Email alert for 'lung tumor' (number: 6564021)

(this option only available for Drugs)

Optionally restrict to(you can select more than one)

- Development Status Updated
- Chemical Structure Added/Updated
- Reference Added
- Literature Evaluation Added
- Indexing Updated
- Licensing Information Updated
- Editorial Amendments

步骤 5

选择接受跟踪服务时您需要的最新/附加信息

例
 如果您需要了解最新发展状况：
 当发展状况更新时，跟踪服务将会自动发送给您。

(* 注意当您选择了任意一个选择框，跟踪系统只对老信息基础上有所更新的内容进行通知，而对新增加的信息不做通知。

如果您没有选择任何一个选择框，则无论是对更新还是新增加的信息都会进行通知。)

点击 Next

SAVE FORM SEARCH - DRUGS

Update my saved search

Daily Weekly 4-Weekly


Notify me if zero results

步骤 6 设置跟踪频率

提供选项：
 每天，每周，每4周

当只有0个结果时，选择您是否需要提示信息

点击 Save



步骤 7
完成跟踪服务的设置




步骤 8
修改跟踪服务的设置

若要修改或确认您的跟踪服务，请到文件夹进行操作

电子邮件跟踪服务将会提交如下信息：

From: Thomson Pharma by email [mailto:alerts@thomson-pharma.com]
Sent: Thursday, December 07, 2006 5:12 PM
To: Inada, Mami (TS - Asia)
Subject: Saved Search Alert 'lung cancer'



列出与您的检索相匹配的报告。
 列表中显示报告数量。
 若要查看检索结果，点击“click here”。

只要您登录 Thomson Pharma，检索结果就会显示出来。
 点击药物名称可以看到某种药物的报告。

Number of Reports
 Drug 7 DR

Display by [?] Help
 Summary

Sort by [?] Help
 Date
 Ascending OR
 Descending order

Rank by [?] Help
 Select

Go to Form Search

Search Strategy
 You searched for: **My Form Search, Drugs:** "egfr family tyrosine kinase receptor inhibitor"+ [Action] AND "lung tumor"+ [Therapy Area] AND ("us" [Country] OR "japan" [Country]) AND restricted to update date, latest 2 weeks

Process results

Summary

Select all [Show Checked](#)

cetuximab DR
 Updated on 29 August 2007. Originator: ImClone Systems Inc. Highest Dev Status: Launched.

EGF vaccine (cancer), CIMAB/ Micromet/Biocon/Bioven DR
 Updated on 29 August 2007. Originator: The Center of Molecular Immunology. Highest Dev Status: Phase 3 Clinical.

erlotinib DR
 Updated on 21 August 2007. Originator: OSI Pharmaceuticals Inc. Highest Dev Status: Launched.

以下信息供您参考：

药物报告由于下列“更新原因”而被跟踪

Drug Report

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS GENERIC COMPETITION MESSAGE MAPPING BIBLIOGRAPHY

SUMMARY DRUG NAME

SUMMARY

Drug name
[Company](#)
 Highest dev statu
[Therapy areas](#)
[Actions](#)
[Technologies](#)
 Target
 EphMRA Code
 Update date
 Reason for update

更新原因如下

1. 最新发展状况
2. 化学结构的添加/更新
3. 参考书目的添加
4. 文献评价的添加
5. 最新标定指数(治疗领域/作用机制/工艺技术)
6. 最新许可证信息
7. 编辑上的更正

Nicotinic ACh receptor alpha 4 subunit; Nicotinic ACh receptor beta 2 subunit

11 June 2008

Indexing Updated, One or More Development Status Entries Have Been Updated, 1 Reference Added [915122]

下面介绍在药物报告里如何找到“更新原因”

1. 最新发展状况

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS GENERIC COMPETITION MESSAGE MAPPING BIBLIOGRAPHY

DEVELOPMENT STATUS DEVELOPMENT STATUS HISTORY THERAPEUTIC USE SCIENTIFIC DATA AND CLINICAL SECTION BIBLIOGRAPHY

DEVELOPMENT STATUS i

Detailed Status for AstraZeneca plc				
Therapy Area	Country	Status	Reference	Date
Alzheimers disease	Canada	Phase 2 Clinical	815034	23 July 2007
Alzheimers disease	Europe	Phase 2 Clinical	815034	23 July 2007
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	915122	10 June 2008
Cognitive disorder	Canada	Phase 2 Clinical	824725	23 August 2007
Cognitive disorder	US	Phase 2 Clinical	642785	28 December 2005

Detailed Status for Targacept Inc				
Therapy Area	Country	Status	Reference	Date
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	915122	10 June 2008

2. 化学结构的添加/更新

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS GENERIC COMPETITION MESSAGE MAPPING BIBLIOGRAPHY

CHEMISTRY CAS RN SCIENTIFIC DATA / CHEMISTRYSECTION BIBLIOGRAPHY

CHEMISTRY i

Selected compound Confidence level: 1

[View Mol File](#)
[CJ-13-610](#)

3 参考书目的添加

参考书目列表（显示了所有的参考书目，您可以快速浏览标题，来源，出版日期）

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS GENERIC COMPETITION MESSAGE MAPPING BIBLIOGRAPHY

BIBLIOGRAPHY

BIBLIOGRAPHY i

Total linked references : 122 [\(Full results list\)](#) First 20 shown. [View all](#)

915122 Targacept and AstraZeneca begin phase II trial of AZD-3480 Targacept Inc Press Release , 2008:June 10 , Article type: Commercial
914236 NCT00689559: Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects www.clinicaltrials.gov , 2008 , Article type: Commercial

您可以确认每一个列表的参考书目如何被用于药物报告。

概要列表（它显示了关于药物发展的一般概要）

OVERVIEW ⓘ

[Targacept](#) (formerly a subsidiary of [RJ Reynolds](#)) and licensee, [AstraZeneca](#), is developing ispronicline (TC-1734, AZD-3480; structure shown), the lead in a series of nicotinic acetylcholine (nACh) agonists, as a potential oral treatment for Alzheimers disease (AD), schizophrenia-associated cognitive deficits and cognitive impairment including mild cognitive impairment (MCI), age-associated memory impairment (AAMI), attention deficit hyperactivity disorder (ADHD) and other dementias [[512600](#)], [[545766](#)], [[642785](#)], [[762824](#)], [[915122](#)]. Phase II trials in memory and cognitive disorders in elderly people had been initiated by November 2003 [[512600](#)]; in December 2006, following completion of safety and characterization studies, AstraZeneca decided to continue development [[753585](#)], [[762817](#)]. In July 2007, AstraZeneca began a phase IIb trial for mild-to-moderate AD. At that time, the company expected to begin a phase IIb trial for schizophrenia-associated cognitive deficits in August 2007 [[815034](#)]; the trial began in August 2007 [[824725](#)]. A phase II ADHD trial was initiated in June 2008. At that time, the phase II trials for AD and schizophrenia-associated cognitive deficits were expected to be completed in the second half of 2008 [[915122](#)].

发展状况列表

(您可以在表格中看到药物的发展状况，以每一个公司、国家和治疗领域的形式显示。)

DEVELOPMENT STATUS ⓘ

Detailed Status for AstraZeneca plc				
Therapy Area	Country	Status	Reference	Date
Alzheimers disease	Canada	Phase 2 Clinical	815034	23 July 2007
Alzheimers disease	Europe	Phase 2 Clinical	815034	23 July 2007
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	915122	10 June 2008
Cognitive disorder	Canada	Phase 2 Clinical	824725	23 August 2007
Cognitive disorder	US	Phase 2 Clinical	642785	28 December 2005

如果更新原因是“参考书目的添加”，同时也会提供参考书目的文献评价更新。

4. 文献评价的添加

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
LITERATURE EVALUATION DRUGDEX EVALUATIONS SCIENTIFIC DATA / BIOLOGY AND METABOLISM SECTIONS BIBLIOGRAPHY								

LITERATURE EVALUATION ⓘ

Hugo Geerts, In , Philadelphia, USA

Submission date: 27 August 2005

Publication date: 10 December 2006

Introduction

With the observation that a nicotinic acetylcholine (ACh) receptor (nAChR) deficit occurs in neurodegenerative conditions, such as Alzheimer's disease, and in psychiatric conditions, such as schizophrenia, there came a considerable interest in developing nicotinic receptor modulators with a less addictive and toxic profile than nicotine [[624142](#)], [[624143](#)]. Although different nAChR

5. 最新标定指数 (最新治疗领域/作用机制/工艺技术)

Drug Report

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
SUMMARY DRUG NAME BREAKING NEWS OVERVIEW DEALS								

SUMMARY

Drug name	ispronicline
Company	Targacept Inc
Highest dev status	Phase 2 Clinical
Therapy areas	Alzheimers disease; Attention deficit hyperactivity disorder; Cognitive disorder
Actions	Neuroprotectant; Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator; Nicotinic acetylcholine receptor agonist; Nootropic agent; Psychomodulator
Technologies	Oral formulation
Target	Nicotinic ACh receptor ; Nicotinic ACh receptor alpha 4 subunit ; Nicotinic ACh receptor beta 2 subunit
EphMRA Code	N6D
Update date	11 June 2008
Reason for update	Indexing Updated,One or More Development Status Entries Have Been Updated,1 Reference Added [915122]

6. 最新许可证信息 概要列表

DEALS [i](#)

Summary		[Deal Report]
Primary company	Targacept Inc	
Partnering company	AstraZeneca plc	
Deal Type	Drug - Development/Commercialization License	
Start date	28 December 2005	

Overview

In December 2005, [AstraZeneca](#) and [Targacept](#) entered into an exclusive, global research and license agreement for the development and commercialization of [TC-1734](#), to treat Alzheimer's disease (AD), cognitive deficits in schizophrenia and other cognitive disorders [[642914](#)], [[642785](#)]. In February 2006, Targacept received an upfront payment from Astrazeneca [[648681](#)]. In December 2006, AstraZeneca paid developmental milestone payment to Targacept [[753585](#)]. In November 2007, [AstraZeneca](#) acquired an option for an exclusive license to Targacept's [TC-5619](#) [[847728](#)].

7. 编辑上的更正

这种更正的常见例子是会议或其他消息来源的附加数据，但是并不属于最新发展状况列表或最新标定指数。目前尚无法显示这些更新出现在何处。